ArticleGlobal advances in integrative medicine and health
Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial.
Article in Global advances in integrative medicine and health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic Effects of High-Intensity Interval Training andInternational journal of molecular sciences · 2025Trial
- Integrated Phytochemical, Network Pharmacology, and Molecular Docking Analyses of Triphala Extract Reveal Protective Effects Against HLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triphala, a classical polyherbal formulation in Ayurvedic medicine, has traditionally been used for its diverse therapeutic properties, particularly its antioxidant, anti-inflammatory, and immunomodulatory effects. Objective: This study aimed to evaluate changes in oxidative stress, antioxidant activity, and systemic inflammation following Triphala supplementation in individuals with post-COVID-19 condition. Methods: Seventy-four participants (aged 18-53 years) with a history of COVID-19 were enrolled in a preliminary randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive either placebo (n = 37) or Triphala (1000 mg/day; n = 37) capsules, taken 5 days per week for 8 weeks. Biomarkers assessed included malondialdehyde (MDA), protein carbonyl, superoxide dismutase (SOD), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α), measured before and after supplementation. Results: In the Triphala group, MDA ( Conclusion: Triphala supplementation may help reduce oxidative stress and systemic inflammation in individuals with post-COVID-19 condition. Future studies with higher doses or longer treatment durations are recommended to confirm and extend these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.